Researchers said a study showed that while caspofungin was safe and tended to reduce rates of invasive candidiasis in ICU patients, the effect was not significant. They said the study, published in Clinical Infectious Diseases, did provide a proof of concept for beta-glucan monitoring and pre-emptive therapy, and a way to identify at-risk patients.

Related Summaries